Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From JN's article:
Our take on the story is that there is simply TOO MUCH GOING ON at Amarantus to keep the stock under ten cents for much longer.
(caps are mine)
8/8/14
@slurrpie123: $AMBS "We don't foresee significant dilution, only warrants. We don't plan to do a raise to fund our current operations." @G_Commish
@G_Commish: @slurrpie123 correct - we stand by that.
Excellent post
He's been selling shares all year and the pps has almost tripled in the meantime
Thank you for clarifying
It says "together with general controls (including prescription-use restrictions) applicable to the devices"... applicable means appropriate, relevant, pertinent not mandatory or definite
Sorry Simpsonly, I thought I was replying to one of the other posters with my previous response. I appreciate this post you did on the historical value of BIEL's pps and it's potential moving forward. Great work as always!
To state the obvious, it's not unusual for a company to have losses prior to FDA approval. They have products that have been clinically proven to work. They are going through the steps of applying for FDA approval. The FDA itself has proposed a possible path for that to happen and the outcome has not been determined yet.
This is a good reference for considering the pps and value of the company as well as it's potential - Moderators, this should be posted/sticky to the top of the board IMO
The FDA is the one who proposed reclassification to create the possibility for BIEL to bring these products to market.
BIEL's products are clinically proven to work and they meet an unmet need for affordable, drug-free pain relief in a market segment potentially worth billions worldwide.
No one tried to hide the losses. BIEL has developed innovative products that meets an unmet need for affordable, drug-free pain relief and it's going through the FDA approval process so that it can bring these products to market. This process requires a lot investment to build a team and run clincal trails. The losses were not hidden and were not a surprise.
Great! Thanks for calling!!
Great! Very well presented!
Exactly - well said
Interesting to look back just a few months and see how far they've come along on their strategies.
They've got a product that has been clinically proven to work, it's innovative and game changing technology that is just beginning to go mainstream, the FDA itself has proposed a new possible way for it to potentially become FDA approved, it was only launched a few months ago in other countries and by Boots, the largest pharmacy retailer in the UK which by-the-way happens to be partially owned by Walgreen's so they've got their attention, the products get positive reviews from customers and are starting to gain attention with reviewers in publications and social media, the products meet an unmet need for affordable, drug-free pain relief with a market potential that's in the billions worldwide not to even mention the potential for a buyout upon FDA approval. It's true that all of the above did not happen overnight and without the need to raise funds, which is why they are a public company and not private. And, just to reiterate, it really doesn't matter how many times anyone posts that the products are no good because it's been clinically proven that they do work.
The advantages of the Actipatch over the products using the TENs technology can be researched on the BIEL website. I saw a TV commercial for the other product though and I think it's great how this overall type of treatment is starting to get traction in the marketplace as people become more aware of new affordable options for dealing with pain. The stage is being set for these types of products to become adopted as a mainstream form of treatment for pain and it seems like a really great time for BIEL to be entering the marketplace if/once they obtain FDA approval.
Past events are all part of the challenging process of starting and building a company and launching an innovative product that's been clinically proven to work and solves an unmet need for effective, affordable, drug-free pain relief. The FDA itself has proposed a way for making FDA approval a possibility and with each day that passes we get closer to learning the outcome.
UP!!!!!
Tweet from someone in the UK who is a health/fitness coach:
"I have been using @ActiPatch for my lower back pain. I am happy to say the pain has subsided and I am able to train without any discomfort."
This is an exchange from Twitter between the person trying out the Actipatch for the FibroMapp Pain
App and a 2nd person named Shannon:
On Apr 28 from Shannon: Nothing like forgetting to take your morning pills will remind you that you hurt far worse than you thought you did. #damnyoufibro #spoonie
On May 1 from FibroMapp Pain App: For me it all hits around 3pm...every. Single. Day. :) #fibromyalgia
23h agp from Shannon: Forgetting to take pills? or the worst pain of the day is at that time? for me worst pain is always in the evenings.
16h ago from FibroMapp Pain App: The pain starts at 3pm and progresses on. In saying that I'm trying the #Actipatch and so far a reduction in pain! I'm impressed!
Someone who operates a pain management app for people with Fibromyalgia called FibroMapp has been testing the Actipatch and posting their progress with it on Twitter and Facebook:
#1 - April 29 at 12:50pm:
Got my free ?#?Actipatch? sample and I am going to give it a go! I have heard nothing but positive things about this little device! Here's hoping! x
#2 - Trying my new #Actipatch for pain - #Arthritis and #Fibromyalgia. Will keep you posted about whether it's helping! #fibro #oa #fm #fms #spoonies
#3 - 3 hours ago
Ok. So I am on Day 2 of using the Actipatch (you only take it off to bathe/shower and put it right back on again). I haven't needed to use ice or my heating pad on my neck until now and have been sitting up instead of lying in a prone position on the computer. And apparently the longer you wear it the more it will help. Excellent for arthritis as well as fibro. You can get a free sample by going to www.actipatch.com what do you have to lose?!
Thanks for all of your DD and efforts in posting - I appreciate your's and other's insights and perspectives!
Agree on all points - Great indeed
That is so very true - it's so exciting to think about this form of treatment becoming mainstream and people having access to this effective method for treating persistent pain issues.
The Test Pit - REVIEW: ActiPatch Knee Pain Relief
http://www.thetestpit.com/2014/04/review-actipatch-knee-pain-relief.html
Steve Jobs personally answered emails sent by the public...
FYI: ActiPatch® Compared to TENS Technology for Pain Relief
"The ActiPatch® and TENS technology provide different clinical applications. ActiPatch® repairs and regenerates damaged cells by reducing pain and inflammation and accelerating blood flow. Whereas, TENS is only blocking pain signals and has no healing effect."
http://www.actipatch.com/blogs/news/13377813-actipatch-compared-to-tens-technology-for-pain-relief
From BIEL Investor Update - Clinical Research Update
BioElectronics has undertaken a series of high quality placebo controlled, randomized control trials to support the safety and efficacy of its medical devices, ActiPatch, RecoveryRx, Allay and the Smart Insole. With the recent FDA recommendation to change the classification of the ILX nonthermal diathermy device category from class III to class II, data derived from these clinical trials will be used to support market clearance in the US through new 510Ks. An update on the progress of the clinical trials is given below. We believe that with this additional clinical data, planned so that more than one study can be used to support each 510K application will lead to market clearance in the US.
The following is a short summary of the progress in our current clinical trials:
1) Plantar Fasciitis: clinical is complete and the results confirm the first studies results and will support 510K applications for ActiPatch musculoskeletal pain and Smart Insole.
2) Osteoarthritis of the Knee and Acute Lower Back Pain: recruitment is finished and the clinical data is now being analyzed. We anticipate that these data will support the ActiPatch 510K and arthritis sales.
3) 3rd Molar Extraction: This study is recruiting rapidly and data will be available to support the RecoveryRx 510K. 3rd Molar extractions are a good model for post-operative pain.
4) Bilateral Hernia Surgical Recovery: Completion is anticipated to be October 2014. However, an interim analysis will be conducted in June to supply data to support the RecoveryRx 510K.
Details of the clinical trials are shown in the table below (see website). Also note that the two published clinical studies on postoperative pain and plantar fasciitis will also be used to support the new 510K application for RecoveryRx and ActiPatch/Smart Insole respectively.
BioElectronics Ongoing Clinical Trials April 2014
In addition to the randomized control trials listed above we will be adding clinical trials on Dental Implant Surgery and Menstrual Pain. Further details will be made available shortly. The Dental Implant clinical trial will be conducted by Drs Operti and Tealdo who have being using RecoveryRx for a number of years and recently authored a white paper which can be viewed here. We are also continuing to expand on the clinical application of ActiPatch and case studies are being planned for Migraine headaches and a number of other indications.
An independent study of venous stasis ulcers (Aarhus University Hospital, Denmark) will be completed in the Fall of this year.
Can you imagine being able to walk in a store and being able to buy one of these - I'd love to be able to do that.
LOL! Best wishes for her speedy recovery!!!
3/19 - Maxim Group reiterates Buy on Galena Biopharma
3/20 - MLV & Co lowers Galena Biopharma’s price target to $5, reiterates Buy
3/19 - Oppenheimer maintains Outperform on Galena Biopharma
3/18 - Noble Financial maintains Buy on Galena Biopharma
3/18 - Roth Capital lowers Galena Biopharma’s price target to $7, Reiterates Buy
3/18 - Piper Jaffray lowers Galena Biopharma’s price target to $6, Reiterates Overweight
Needham & Company Defends Galena Biopharma (GALE)
Needham & Company analyst Chad Messer, Ph.D. has come out to defend Galena Biopharma (NASDAQ: GALE), which was down 12.4% today after the company disclosed an SEC investigation related to an outside investor-relations firm that they retained in 2013.
Messer retained his Buy rating and price target of $9, saying fundamentals are strong despite the stock promotionoverhang. He comment, "Galena currently holds $55.3 million in cash and expects ~$8 million/quarter in operating burn during 2014, leaving the company well capitalized. Management increased 2014 Abstral net revenue guidance and we look for significant progress from the company's pipeline this year. GALE shares have been under substantial pressure since mid-January due to an alleged stock promotion scheme. While we acknowledge the risks associated with the ongoing shareholder lawsuits and SEC investigation, we maintain our Buy rating based on the fundamentals of the company's pipeline."
Noble Financial Remains Netural on Galena's (GALE) Legal Issues; Maintains 'Buy' Rating
Noble Financial maintains Galena Biopharma (Nasdaq: GALE) at Buy with a price target of $6.
Analyst Rahul Jasuja noted that Galena's pipeline remains robust amid recent turbulance in the shares. The analyst said Noble also isn't taking a stance on the legal issues with Galena. The analyst also offered the following observations following recent quarterly results:
- ABSTRAL: Abstral net revenues for 2013 were $2.5M (guidance $1.5 to 3M), $1.2M for 3Q13 and $1.3M for 4Q13; Company has increased 2014 Abstral projections from $8-12M to $11-15M; our model is on the conservative side, $10-12M
- NEUVAX: Phase 3 (PRESENT trial) for breast cancer recurrence - 700 patient enrollment expected to complete in 2014; interim analysis at 70 events expected later in 2014; Phase 2b NeuVax plus Herceptin trial will also complete enrollment in 2014
- GALE-301: Folate binding protein (FBP) vaccine initiated Phase 2 study to prevent recurrence in high risk ovarian cancer patients; Phase 1 top-line results presented in 2013, detailed results of Phase 1 will be presented in 2014
- GALE-401 acquisition: controlled release Anagrelide with improved pk metrics will be developed under 505b2 path for essential thrombocythemia (ET) with Anagrelide-IR as reference drug; Phase 2 to begin mid 2014; US sales potential of $150 to $200M
"Walgreens, the largest drugstore chain in the US, acquired 45% of Alliance-Boots."
Agreed, and actually the stock only traded above the $7 level for just a hand full of days - it's not like it had been there for months and then dropped.
Good post
He's on ignore - I don't even see his posts